FindTrial
Sign In

Functional RMN study to evaluate the prompt and middle term effect of the treatment with Donepezil in patients affected by multiple sclerosis and mild impairment of cognitive function. - ND

Functional RMN study to evaluate the prompt and middle term effect of the treatment with Donepezil in patients affected by multiple sclerosis and mild impairment of cognitive function. - ND

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-001940-38-IT
Enrollment
Unknown
Registered
2008-04-14
Start date
2008-04-22
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients affected by multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis

Interventions

Trade Name: ARICEPT Pharmaceutical Form: Coated tablet INN or Proposed INN: Donepezil Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Trade Name: ARICEPT Pharma

Sponsors

OSPEDALE S. RAFFAELE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients affected by relapsing and remittent SM primarily progressive with a mild cognitive impairment, defined by a score minor than cut off at at least 1 memory test and/or on execution and attention, or to 2 tests related to the same functions; age between 18 and 65; patients able to give their informed consent. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: to evaluate, by functional RMN, the changes in activation of cortical area involved in execution of cognitive tasks in pre and post treatment phase.;Secondary Objective: to quantify evenctual changes of global scores during neuro psychological evaluation conducted before and after the beginning of the treatment.;Primary end point(s): to evaluate, by functional RMN, the changes in activation of cortical area involved in execution of cognitive tasks in pre and post treatment phase.—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026